Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Simultaneous Determination of Pioglitazone and Curcumin from Chitosan-Based Co-delivery Nanosystem for Diabetes Mellitus Therapy

Alexandru Sava
ORCID logo ,
Florentina Geanina Lupascu
,
Simona-Maria Tătărușanu
ORCID logo ,
Andreea-Teodora Iacob
,
Andrei Dascălu
ORCID logo ,
Bianca-Ștefania Profire
* ORCID logo ,
Ioana-Mirela Vasincu
ORCID logo ,
Maria Apotrosoaei
,
Lenuta Profire
ORCID logo
Version 1 : Received: 17 January 2024 / Approved: 18 January 2024 / Online: 18 January 2024 (13:53:00 CET)

How to cite: Sava, A.; Lupascu, F.G.; Tătărușanu, S.; Iacob, A.; Dascălu, A.; Profire, B.; Vasincu, I.; Apotrosoaei, M.; Profire, L. Simultaneous Determination of Pioglitazone and Curcumin from Chitosan-Based Co-delivery Nanosystem for Diabetes Mellitus Therapy. Preprints 2024, 2024011399. https://doi.org/10.20944/preprints202401.1399.v1 Sava, A.; Lupascu, F.G.; Tătărușanu, S.; Iacob, A.; Dascălu, A.; Profire, B.; Vasincu, I.; Apotrosoaei, M.; Profire, L. Simultaneous Determination of Pioglitazone and Curcumin from Chitosan-Based Co-delivery Nanosystem for Diabetes Mellitus Therapy. Preprints 2024, 2024011399. https://doi.org/10.20944/preprints202401.1399.v1

Abstract

Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic disorders, with a major involvement of oxidative stress in its onset and progression. Pioglitazone (Pio) is an antidiabetic drug which primarily works by reducing insulin resistance while Curcumin (Cur) is powerful antioxidant with o important hypoglycemic effect, also. The both drugs are associated with several drawbacks, such as reduced bioavailability, a short half-life time (Pio) as well as instability and poor water solubility (Cur), which limit their therapeutic use. In order to overcome these disadvantages, a new co-delivery (Pio, Cur) nanosystem based chitosan (CS) (CS-Pio-Cur NPs), was developed, and characterized in reference with simple nanosystems (CS-Pio NPs, CS-Cur NPs). The developed CS-based NPs (CS-Pio-Cur NPs, CS-Pio NPs, CS-Cur NPs) were physico-chemical characterized in terms of particle size (PS), entrapment efficiency (EF%) and loading capacity (LC%). The CS-Pio-Cur NPs proved increased or similar values of EE (88.95% ± 7.79 for Cur; 94.83% ± 9.89 for Pio) and LC% (24.25 % ± 1.62 for Cur; 3.5% ± 0.98 for Pio), in reference with simple nanosystems, CS-Cur NPs (EE = 82.46% ± 1.74; LC = 20.34% ± 0.94) and CS-Pio NPs) (EE = 96.31% ± 0.68; LC = 4.11% ± 0.47), respectively. The identification of APIs (Cur, Pio) loaded into CS matrix was performed using FR-IR spectroscopy and for simultaneously quantification of APIs (Cur, Pio) released from CS-Pio-Cur NPs, a HLPC method was developed and validated. Based on release study performed in different simulated fluids (SGF, SIF, SCF) it can be appreciated that developed CS-APIs NPs have favorable pharmacokinetic profile with good release in gastrointestinal tract.

Keywords

curcumin; pioglitazone; chitosan; co-delivery; nanoparticles; HPLC

Subject

Medicine and Pharmacology, Medicine and Pharmacology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.